Last filing: Mar 4, 2026.
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 0 of the 13 calendar months from Oct 2025 to Oct 2026.
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Eikon Therapeutics, Inc. (EIKN) | Chief Executive Officer and Director, Director | Feb 4, 2026 | Mar 4, 2026 |
| Merck & Co. (MRK) | Former Exe V-P & Pres, MRL | Apr 23, 2013 | May 5, 2020 |
| Amgen (AMGN) | Former EVP, Research & Development | Aug 4, 2003 | Feb 6, 2012 |
Recent filings
The last day with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Feb 6, 2026, Eikon Therapeutics, Inc.: 284,857 shares converted (some held indirectly). 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.